AbbVie income statement

In fiscal 2025, AbbVie reported revenue of $61.16bn, up 8.6% on the year before, operating income of $15.07bn (a 24.6% margin) and net income of $4.23bn, or $2.36 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

AbbVie: income statement, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	17.4	18.4	18.8	20.0	22.9	25.6	28.2	32.8	33.3	45.8	56.2	58.1	54.3	56.3	61.2	66.0
Cost of revenue	—	—	—	—	—	5.8	7.0	7.7	7.4	15.4	17.4	17.4	20.4	16.9	18.2	17.3
Gross profit	—	—	—	—	—	19.8	21.2	25.0	25.8	30.4	38.8	40.6	33.9	39.4	43.0	48.7
Research and development	2.6	2.8	2.9	3.3	4.3	4.4	5.0	10.3	6.4	6.4	6.9	6.5	7.7	12.8	9.1	10.0
Selling, general and administrative	5.9	5.0	5.4	7.7	6.4	5.9	6.3	7.4	6.9	11.3	12.3	15.3	12.9	14.8	14.0	15.2
Operating income	3.6	5.8	5.7	3.4	7.5	9.3	9.5	6.4	13.0	11.4	17.9	18.1	12.8	9.1	15.1	21.2
Interest expense	—	0.1	0.3	0.4	0.7	1.0	1.2	1.3	1.8	2.5	2.4	2.2	2.2	2.8	2.9	3.0
Income before tax	3.7	5.7	5.3	2.4	6.6	7.9	7.7	5.2	8.4	3.4	13.0	13.5	6.3	3.7	6.6	12.8
Income tax	0.2	0.5	1.2	0.6	1.5	1.9	2.4	−0.5	0.5	−1.2	1.4	1.6	1.4	−0.6	2.4	2.5
Net income	3.4	5.3	4.1	1.8	5.1	6.0	5.3	5.7	7.9	4.6	11.5	11.8	4.9	4.3	4.2	10.3
Diluted EPS	$2.18	$3.35	$2.56	$1.10	$3.13	$3.63	$3.30	$3.66	$5.28	$2.72	$6.45	$6.63	$2.72	$2.39	$2.36	$5.83
Diluted shares (average)	1,577m	1,577m	1,604m	1,610m	1,637m	1,631m	1,603m	1,546m	1,484m	1,673m	1,777m	1,778m	1,773m	1,773m	1,773m	1,774m
EBITDA	4.1	6.3	6.1	3.8	8.0	9.8	10.0	6.9	13.4	12.0	18.7	18.9	13.5	9.9	15.8	22.0

US$ billions unless shown otherwise. Fiscal quarters.

AbbVie: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	15.1	13.3	15.4	15.8	16.6	15.0	17.0	17.4
Cost of revenue	4.4	4.0	4.3	5.3	4.6	4.2	4.3	4.3
Gross profit	10.7	9.3	11.1	10.5	12.1	10.8	12.7	13.1
Research and development	6.8	2.1	2.1	2.3	2.6	2.5	2.3	2.6
Selling, general and administrative	3.9	3.3	3.3	3.6	3.9	3.6	3.6	4.1
Operating income	−1.5	3.7	4.9	1.9	4.5	4.0	6.4	6.3
Interest expense	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8
Income before tax	−2.3	1.7	1.6	0.7	2.7	1.0	4.3	4.8
Income tax	−2.2	0.4	0.6	0.5	0.9	0.3	0.7	0.6
Net income	−0.0	1.3	0.9	0.2	1.8	0.7	3.6	4.2
Diluted EPS	−$0.02	$0.72	$0.52	$0.10	$1.02	$0.39	$2.03	$2.37
EBITDA	−1.3	3.9	5.1	2.1	4.7	4.2	6.6	6.5

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABBV vs AMGN ABBV vs GILD ABBV vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AbbVie's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AbbVie.